Vascular Biogenics Ltd. (NASDAQ:VBLT) finished Friday with a subtraction of -$0.02 to close at $0.23, a downside of -7.96 percent. An average of 766,120 shares of common stock have been traded in the last five days. There was a fall of -$0.0267 in the past week, and it reached a new high 5 times over the past 12 months. The last 20 days have seen an average of 1,107,025 shares traded, while the 50-day average volume stands at 1,520,944.
VBLT stock has decreased by -25.75% in the last month. The company shares reached their 1-month lowest point of $0.2222 on 08/07/23. With the stock rallying to its 52-week high on 07/13/23, shares of the company touched a low of $0.10 and a high of $0.32 in 52 weeks. It has reached a new high 12 times so far this year and achieved 91.75% or $0.1101 in price. In spite of this, the price is down -28.09% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Vascular Biogenics Ltd. (VBLT) stock’s beta is 0.81. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 35.09, the price-to-book (PB) ratio at 0.89.
Financial Health
The quick ratio of Vascular Biogenics Ltd. for the recent quarter was 3.50, and the current ratio was 3.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the recent quarter. Vascular Biogenics Ltd.’s EBITDA margin is -4832.07%. Its gross profit as reported stood at $0.55 million compared to revenue of $0.66 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Vascular Biogenics Ltd.’s return on assets was -70.70%.
Earnings Surprise
The company posted a net income of $2.64 million in the quarter, while revenues of $32.3 million were grew 100.0%. At the end of the recent quarter, Vascular Biogenics Ltd.’s stock balance sheet showed total liabilities of 8.21 million. Shareholders own equity worth $70.5 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Vascular Biogenics Ltd. (VBLT) price momentum. RSI 9-day as of the close on 11 August was 30.88%, suggesting the stock is Neutral, with historical volatility in this time frame at 63.33%.
As of today, VBLT’s price is $0.2453 -10.40% or -$0.0267 from its 5-day moving average. VBLT is currently trading -21.81% lower than its 20-day SMA and +73.66% higher than its 100-day SMA. However, the stock’s current price level is +9.62% above the SMA50 and +75.51% above the SMA200.
The stochastic %K and %D were 25.53% and 30.00%, respectively, and the average true range (ATR) was 0.0266. With the 14-day stochastic at 9.02% and the average true range at 0.0265, the RSI (14) stands at 37.74%. The stock has reached -0.0155 on the 9-day MACD Oscillator while the 14-day reading was at -0.0276.
Analyst Ratings
Oppenheimer downgraded Vascular Biogenics Ltd. (NASDAQ: VBLT) to a a Perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform.
